Zuclopenthixol

Zuclopenthixol is a tranquillizer, similar to chlorpromazine. Zuclopenthixol is used in the treatment of schizophrenia.

Zuclopenthixol is primarily indicated in conditions like Dementia, Enhance permeation of SC or IM inj, Labyrinthine disorders, Mania, Prolactinoma, Psychosis, Schizophrenia, Second trimester abortion.

Zuclopenthixol is contraindicated in conditions like Alcohol dependence, Parkinsonism, Pheochromocytoma, Coma, CNS depression.

Zuclopenthixol produces potentially life-threatening effects which include Fever, Neuroleptic Malignant Syndrome, Hypertonicity. which are responsible for the discontinuation of Zuclopenthixol therapy.The signs and symptoms that are produced after the acute overdosage of Zuclopenthixol include Convulsions, Coma, Hypothermia, Somnolence, Extrapyramidal effects. The symptomatic adverse reactions produced by Zuclopenthixol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Tachycardia, Parkinsonism, Akathisia, Loss of libido, Dystonic reactions, Menstrual irregularity, Orthostatic hypotension, Benign leucopenia, Tardive dyskinesia.

Zuclopenthixol should be used with caution in patients exposed to extreme heat or phosphorus insecticides, patients in state of alcohol withdrawal, patients with history of peptic ulcer, allergic reactions, with renal impairment, prostatic hypertrophy. Photosensitization may occur, caution patients to take appropriate measures (e.g. wear protective clothing or sunscreen) against exposure to sunlight or UV light. Discontinue use at least 48 hrs before myelography.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

20 to 30 mg (25 (25)) 24 hourly PO — Initial 20 to 50 mg (35 (35)) 8 hourly PO — Maintenance 200 to 400 mg (300 (300)) As recommended. IM — Every 2-4 Week

( ) — Not recommended in this age group

( ) — Not recommended in this age group

Zuclopenthixol is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholGuanethidineMetoclopramide (HCl)ProchlorperazineVORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab, Inj Store Below 25°C. Protect from Sunlight.